<DOC>
	<DOCNO>NCT03101748</DOCNO>
	<brief_summary>The goal clinical research study learn add neratinib either taxol ( paclitaxel ) combination pertuzumab , trastuzumab , paclitaxel help control metastatic locally advanced breast cancer give standard chemotherapy ( doxorubicin and/or cyclophosphamide ) surgery . Researchers also want find high tolerable dose neratinib use study drug combination . The safety drug combination also study .</brief_summary>
	<brief_title>3HT With Taxol Metastatic Breast Cancer</brief_title>
	<detailed_description>Study Groups : If participant find eligible take part study , participant assign 1 3 study group base participant 's screening result : - If participant Group A B , participant receive neratinib , paclitaxel , pertuzumab , trastuzumab . The difference 2 group dose neratinib paclitaxel may different participant Group A , participant Group B receive dose . - If participant Group A , participant assign dose level neratinib base participant join study . Up 4 dose level neratinib test . Up 20 total participant enrol Group A . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose neratinib find . - If participant Group B , participant receive doxorubicin cyclophosphamide receive 4 cycle drug list . - If participant Group C , participant receive neratinib paclitaxel follow doxorubicin cyclophosphamide . Study Drug Administration : All participant take neratinib 1 time day mouth first week 1-week `` pre-cycle '' . After , study cycle 21 day long participant 's drug administration schedule depend group participant . If participant Group A : - Participant take neratinib tablet 1 time day mouth food time day ( morning , possible ) Cycles 1 - 4 . The study doctor tell participant many tablet participant need take every day . - Participant receive paclitaxel vein 1-3 hour Days 1 , 8 , 15 Cycles 1 - 4 . - Participant receive pertuzumab vein 1 hour Day 1 Cycles 1 - 4 - Participant receive trastuzumab vein 1-2 hour Day 1 Cycles 1 - 4 . - After Cycle 4 , participant 's doctor decide kind treatment participant receive next . The study doctor tell participant participant take take . If participant Group B : - Participant take neratinib tablet 1 time day mouth food time day ( morning , possible ) Cycles 1 - 4 . The study doctor tell participant many tablet participant need take every day . - Participant receive paclitaxel vein 1-3 hour Days 1 , 8 , 15 Cycles 1-4 . - Participant receive pertuzumab vein 1 hour Day 1 Cycles 1 - 4 - Participant receive trastuzumab vein 1 - 2 hour Day 1 Cycles 1 - 4 . - Participant receive standard-of-care doxorubicin cyclophosphamide vein 90 minute Day 1 Cycles 5 - 8 . If participant Group C : - Participant take neratinib tablet 1 time day mouth food time day ( morning , possible ) Cycles 1 - 4 . The study doctor tell participant many tablet participant need take every day . - Participant receive paclitaxel vein 1 - 3 hour Days 1 , 8 , 15 Cycles 1 - 4 . - Participant receive standard-of-care doxorubicin cyclophosphamide vein 90 minute Day 1 Cycles 5 - 8 . If participant Group B C , participant standard-of-care surgery participant finish receive doxorubicin cyclophosphamide . Participant receive separate consent form surgery describe procedure risk . Length Study : Participant receive 8 cycle study drug . Participant longer able take study drug disease get bad , intolerable side effect occur , participant unable follow study direction . Participation study follow-up period . Study Visits : If participant Group A : - Before Day 1 Cycle 1 , participant breast core biopsy collect tissue biomarker test . - Before Day 1 Cycles 1 - 4 , participant begin next treatment , participant physical exam include breast lymph node exam . - Before Day 1 Cycle 1 participant begin next treatment Cycle 4 , study doctor take picture participant 's breast . - On Days 1 , 8 , 15 Cycles 1 - 4 participant begin next treatment Cycle 4 , blood ( 1-3 tablespoon ) drawn routine test . - Before Day 1 Cycle 1 , participant begin next treatment Cycle 4 , participant mammogram involve breast ultrasound involve breast lymph node . Participant may breast MRI doctor think need . If participant Group B C : - Before Day 1 Cycle 1 , participant breast core biopsy collect tissue biomarker test . - Before Day 1 Cycles 1 - 5 , last dose doxorubicin cyclophosphamide , surgery , participant physical exam include breast lymph node exam . - Before Cycle 1 Cycle 5 , surgery , study doctor take picture participant 's breast . - On Days 1 , 8 , 15 Cycles 1 - 5 surgery , blood ( 1-3 tablespoon ) drawn routine test . - Before Day 1 Cycle 1 , participant begin receive doxorubicin cyclophosphamide , surgery , participant mammogram involve breast ultrasound involve breast lymph node . Participant may breast MRI doctor think need . - During surgery , breast tissue sample collect identify tumor routine test biomarker test . No additional breast tissue remove addition would already remove surgery . Follow-Up : About 1 month surgery , participant ask participant 's health side effect participant may . Participant may ask routine clinic visit participant may call member study staff . If participant call , call last 2 minute . This investigational study . Pertuzumab trastuzumab FDA approve commercially available treatment HER2-positive breast cancer . Paclitaxel , doxorubicin , cyclophosphamide FDA approve commercially available treatment breast cancer . Neratinib FDA approve commercially available . The drug combination investigational currently use research purpose . The study doctor describe study drug design work . Up 99 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histological confirmation breast cancer 2 . 18 year age old 3 . Able provide write informed consent trial 4 . Performance status &lt; /= 1 ECOG performance scale 5 . Able swallow oral medication 6 . LVEF assessment 2D echocardiogram MUGA scan perform within 90 day prior registration must &gt; /= 50 % 7 . 7 . Adequate organ function determine follow laboratory value : Absolute neutrophil count &gt; /= 1,500 /uL , Platelets &gt; /= 100,000 / uL , Hemoglobin &gt; /=9 g/dL , Creatinine clearance &gt; /= 50 ml/min , Total bilirubin &lt; /= 1.5 X ULN , patient congenital unconjugated hyperbilirubinemia ( CriglerNajjar syndrome type 1 2 , Gilbert syndrome ) transient hyperbilirubinemia occur due physiological condition , long clear documentation diagnosis , allow enrol direct ( conjugate ) bilirubin â‰¤ 1.5 X ULN , Alanine aminotransferase aspartate aminotransferase &lt; /= 2.5 X ULN except patient AST/ALT elevation declare cause due liver metastasis , allow enrol long &lt; 5 x ULN . 8 . Subject Childbearing potential willing use effective method birth control surgically sterile , abstain heterosexual activity study least 4 month last dose study drug . Subject childbearing potential define surgically sterilize free menses &gt; 1 year . 9 . Subject childbearing potential willing use effective method birth control include : 1 ) Use hormonal birth control method : pill , shots/injections , implant ( place skin health care provider ) , patch ( place skin ) ; 2 ) Intrauterine device ( IUDs ) ; 3 ) Using 2 barrier method ( partner must use 1 barrier method ) spermicide . Males must use male condom ( latex synthetic material ) spermicide . Females must choose either Diaphragm spermicide , Cervical cap spermicide , sponge ( spermicide already contraceptive sponge ) . Female patient childbearing potential must negative urine pregnancy test 21 day prior start study drug ; 4 ) For male participant , must agree commit use barrier method contraception treatment 3 month last dose investigational product . 10 . Cohort 1 : Phase 1b : Subject must HER2 + ( regardless hormonal receptor status ) primary metastatic locally advanced breast cancer ( IBC NonIBC ) . HER2 positive status define strongly positive ( 3+ ) stain score IHC , gene amplification use FISH , perform . If IHC equivocal ( 2+ ) , assay use FISH require gene amplification base recent ASCOCAP guideline : dualprobe HER2/CEP17 ratio &gt; /=2.0 and/or average HER2 copy number &gt; /= 6.0 signals/cell . IBC determine use international consensus criterion : Onset : Rapid onset breast erythema , edema and/or peau d'orange , and/or warm breast , with/without underlie breast mass . Duration : History finding 6 month . Extent erythema occupy least 1/3 whole breast . Pathology : Pathologic confirmation invasive carcinoma 11 . Cohort 1 : Phase II : Patient must HER2+ ( regardless hormonal receptor status ) stage III IBC . 12 . Cohort 2 Patient must HER2/ER+ stage III IBC . HER2 negative status , determine assays use IHC require negative ( 0 1+ ) stain score . If IHC equivocal ( 2+ ) stain score , assay use FISH require absence gene amplification : dualprobe HER2/CEP17 ratio &lt; 2.0 average HER2 copy number &lt; 4.0 signals/cell . If HER2 test result confirm MDACC , require centralized repeat test . Hormone receptor ( HR ) positivity determine ER &gt; 10 % /or PR &gt; 10 % IHC staining . 1 . Excisional biopsy lumpectomy current breast cancer . 2 . Any previous malignancy ( except cervical situ cancer treat local excision , basal squamous cell carcinoma skin ) within 5 year . 3 . Any previous antitumor therapy current cancer event ( previous treatment current diagnosis previous disease free status need confirm ) . This exclusion apply phase Ib part cohort 1 . 4 . Breastfeeding screen plan become pregnant course therapy . 5 . History active know autoimmune disease cause diarrhea like ( limited ) Addison 's Disease , Celiac Disease/Gluten Intolerance/Irritable Bowel Syndrome , Scleroderma . 6 . Active infection chronic infection require chronic suppressive antibiotic . 7 . Active hepatitis B hepatitis C abnormal liver function test . 8 . Malabsorption syndrome , ulcerative colitis , inflammatory bowel disease , resection stomach small bowel , disease condition significantly affect gastrointestinal function . 9 . Persistent &gt; /= grade 2 diarrhea regardless etiology . 10 . Sensory motor neuropathy &gt; /= grade 2 11 . Conditions would prohibit intermittent administration corticosteroid paclitaxel premedication . However , corticosteroid drop confirm asthma like reaction paclitaxel 3 dos . 12 . Uncontrolled hypertension define systolic BP &gt; 150 mmHg diastolic BP &gt; 90 mmHg , without antihypertensive medication . 13 . Cardiac disease ( history and/or active disease ) would preclude use drug include treatment regimen . This include confine : ( A ) Active cardiac disease include : â€¢ symptomatic angina pectoris within past 180 day require initiation increase antianginal medication intervention ; â€¢ ventricular arrhythmia except benign premature ventricular contraction ; â€¢ supraventricular nodal arrhythmia require pacemaker control medication ; â€¢ conduction abnormality require pacemaker ; â€¢ valvular disease document compromise cardiac function ; â€¢ symptomatic pericarditis . ( B ) History cardiac disease : â€¢ myocardial infarction document elevated cardiac enzyme persistent regional wall abnormality assessment LV function ; â€¢ history documented CHF ; â€¢ document cardiomyopathy . 14 . If pregnant , enrol study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Malignant neoplasm breast</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>HER2+</keyword>
	<keyword>HER2-negative/ER-positive</keyword>
	<keyword>HER2-/ER+</keyword>
	<keyword>Locally advanced inflammatory breast cancer</keyword>
	<keyword>IBC</keyword>
	<keyword>Neratinib</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Doxorubicin Hydrochloride</keyword>
	<keyword>Adriamycin PFS</keyword>
	<keyword>Adriamycin RDF</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Rubex</keyword>
	<keyword>Pertuzumab</keyword>
	<keyword>Perjeta</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
</DOC>